( NASDAQ-SMALL:NWBO,OTC-PINK:NWBO,OTC-QB:NWBO )

News from Northwest Biotherapeutics A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages.

Latest

Jan 18, 2017, 15:28 ET NW Bio Presenting At Phacilitate Immunotherapy World Conference

Northwest Biotherapeutics, Inc. (OTCQB: NWBO) ("NW Bio"), a U.S. biotechnology company developing DCVax® personalized immune therapies for operable...


Dec 20, 2016, 09:29 ET NW BIO ANNOUNCES A REGISTERED DIRECT OFFERING OF $10.0 MILLION WITH INSTITUTIONAL INVESTORS

Northwest Biotherapeutics (NASDAQ: NWBO) (NW Bio), a biotechnology company developing DCVax® personalized immune therapies for solid tumor...


Dec 19, 2016, 09:39 ET NW Bio Announces Initiation Of Trading On The OTCQB Marketplace Starting On Monday Morning, December 19, 2016

Northwest Biotherapeutics (Nasdaq: NWBO) ("NW Bio" or the "Company"), a biotechnology company developing DCVax® personalized immune therapies for...


Dec 08, 2016, 14:04 ET NW Bio Provides Update About Phase 3 Trial Of DCVax®-L for Newly Diagnosed Glioblastoma Multiforme Brain Cancer

Northwest Biotherapeutics (Nasdaq: NWBO) ("NW Bio" or the "Company"), a biotechnology company developing DCVax® personalized immune therapies for...


Dec 07, 2016, 20:00 ET NW Bio Announces Decision to Voluntarily Withdraw from Nasdaq Listing and Begin Trading on OTC Market

Northwest Biotherapeutics (Nasdaq: NWBO) ("NW Bio" or the "Company"), a biotechnology company developing DCVax® personalized immune therapies for...


Nov 17, 2016, 08:15 ET NW Bio Announces Phase II Clinical Trial Program Combining DCVax®-L and Pembrolizumab (Keytruda®) for Colorectal Cancer

Northwest Biotherapeutics (NASDAQ: NWBO) ("NW Bio"), a U.S. biotechnology company developing DCVax® personalized immune therapies for solid tumor...


Oct 21, 2016, 09:45 ET NW BIO Announces Registered Direct Offering

Northwest Biotherapeutics (NASDAQ: NWBO) (NW Bio), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers,...


Sep 29, 2016, 09:26 ET NW Bio Presents Further DCVax®-Direct Phase I Trial Information On Individual Patient Survival At NY Cancer Immunotherapy Conference

Northwest Biotherapeutics (NASDAQ: NWBO) ("NW Bio"), a U.S. biotechnology company developing DCVax® personalized immune therapies for solid...


Sep 06, 2016, 08:55 ET NASDAQ Accepts NW Bio Remediation Plan For Shares and Warrants Previously Issued to Cognate BioServices

 Northwest Biotherapeutics (NASDAQ: NWBO) ("NW Bio" or the "Company"), a biotechnology company developing DCVax® personalized immune...


Jul 05, 2016, 09:00 ET NW BIO ANNOUNCES A REGISTERED DIRECT OFFERING OF $3.7 MILLION WITH NEW INSTITUTIONAL INVESTORS

 Northwest Biotherapeutics (NASDAQ: NWBO) (NW Bio), a biotechnology company developing DCVax® personalized immune therapies for solid...


Jun 13, 2016, 09:15 ET NW Bio Announces Scientific Advisory Board

Northwest Biotherapeutics (NASDAQ: NWBO) ("NW Bio"), a U.S. biotechnology company developing DCVax® personalized immunotherapies for solid...


Jan 25, 2016, 09:30 ET NW Bio Announces Appointment Of Two New Independent Directors With Biotech/Pharma Expertise and Cybersecurity/Investigations Expertise

 Northwest Biotherapeutics (NASDAQ: NWBO) (NW Bio), a biotechnology company developing DCVax® personalized immune therapies for solid...


Dec 24, 2015, 16:29 ET NW Bio Announces Closing Of Registered Direct Offering of $12.6 Million

Northwest Biotherapeutics (NASDAQ: NWBO) (NW Bio), a biotechnology company developing DCVax® personalized immune therapies for solid tumor...


Dec 23, 2015, 09:00 ET NW BIO ANNOUNCES A REGISTERED DIRECT OFFERING OF $12.6 MILLION

 Northwest Biotherapeutics (NASDAQ: NWBO) (NW Bio), a biotechnology company developing DCVax® personalized immune therapies for solid...


Dec 21, 2015, 13:05 ET NW Bio Announces Annual Meeting Results, Re-Election of Directors

 Northwest Biotherapeutics (NASDAQ: NWBO) ("NW Bio"), a U.S. biotechnology company developing DCVax® personalized immune therapies for...


Dec 08, 2015, 08:15 ET NW Bio Announces Establishment of Special Committee And Law Firm To Conduct Independent Investigation of Recent Allegations

 Northwest Biotherapeutics (NASDAQ: NWBO)("NW Bio"), a U.S. biotechnology company developing DCVax® personalized immune therapies for...


Dec 08, 2015, 08:15 ET NW Bio Statement Regarding Appointments

 Northwest Biotherapeutics (NASDAQ: NWBO) ("NW Bio"), a U.S. biotechnology company developing DCVax® personalized immune therapies for...


Oct 21, 2015, 12:00 ET NW Bio Has Entered Into An Agreement For $30 Million Of New Equity Funding From Woodford Investment Management

Northwest Biotherapeutics (NASDAQ: NWBO) ("NW Bio"), a U.S. biotechnology company developing DCVax® personalized immune therapies for solid...


Oct 19, 2015, 10:01 ET NW Bio Issues Statement on Highly Unusual Trading Activity

 Northwest Biotherapeutics (NASDAQ: NWBO) ("NW Bio"), a U.S. biotechnology company developing DCVax® personalized immune therapies for...


Sep 16, 2015, 09:20 ET NW Bio Presenting New DCVax-Direct Poster At "The Inaugural International Cancer Immunotherapy Conference: Translating Science Into Survival" In New York City On Wednesday, September 16, 2015

 Northwest Biotherapeutics (NASDAQ: NWBO) ("NW Bio"), a U.S. biotechnology company developing DCVax® personalized immune therapies for...


Sep 14, 2015, 09:51 ET NW to Present at 4th Annual SMi Cancer Vaccines Conference in London On Wednesday, September 16, 2015

Northwest Biotherapeutics (NASDAQ: NWBO) ("NW Bio"), a U.S. biotechnology company developing DCVax® personalized immune therapies for solid...


Nov 07, 2014, 09:15 ET NW BIO MAKING A JOINT POSTER PRESENTATION ON ITS DCVAX-DIRECT TRIAL AT THE 29TH ANNUAL SITC MEETING

Northwest Biotherapeutics (NASDAQ: NWBO) ("NW Bio"), a U.S. biotechnology company developing DCVax® personalized immune therapies for solid...


Oct 07, 2014, 09:00 ET NW BIO ANNOUNCES $11.5 MILLION FINANCING

 Northwest Biotherapeutics (NASDAQ: NWBO) ("NW Bio"), a biotechnology company developing DCVax® personalized immune therapies for solid...


Sep 16, 2014, 08:00 ET NW BIO'S CANCER VACCINE IS THE FIRST DRUG TO BE DESIGNATED BY UK AUTHORITIES AS A "PROMISING INNOVATIVE MEDICINE" (PIM)

Northwest Biotherapeutics (NASDAQ: NWBO) ("NW Bio"), a biotechnology company developing DCVax® personalized immune therapies for solid tumor...


Jun 10, 2014, 08:15 ET DCVAX®-L PHASE III TRIAL INITIATED IN GERMANY

Northwest Biotherapeutics (NASDAQ: NWBO) (NW Bio), a biotechnology company developing DCVax® personalized immune therapies for solid tumor...